Author Archives: Bruno Quinney

Business financing
#Artificial intelligence (AI) #Drug development #Drug discovery #Financing

Tres Alchemix closes $4.4 million financing round

AI-driven biotechnology company Tres Alchemix has closed its $4.4 million Series A financing round, the company has announced.  New funding will be used to accelerate the development of Tres Alchemix’s predictive AI platform and support the opening of a new laboratory at The Oxford Science Park, a hub of world-leading… Read More

#Business & Investment #News #Start-up Zone

Haematology
#Biotech #Financing #Haematology #Immunology

Star Therapeutics announces $125 million financing for VWD therapy

Biotechnology company Star Therapeutics has announced its $125 million Series D financing round was oversubscribed and will now initiate a clinical trial of its von Willebrand disease (VWD) therapy.  The financing round was co-led by Sanofi Ventures and Viking Global Investors, with participation from both… Read More

#News

FDA
#FDA #Orphan drugs

FDA grants Orphan Drug Designation to gMG treatment CNP-106

The US Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an investigational therapy for the treatment of generalised myasthenia gravis (gMG).  CNP-106 is a biodegradable nanoparticle that encapsulates seven acetylcholine receptor (AChR) antigens. It is being evaluated for its potential to induce antigen-specific immune tolerance in… Read More

#News #Regulatory

#Investment #Sanofi

Sanofi strengthens investor start-up fund by $625 million

Sanofi Ventures has announced an additional $625 million multiyear capital commitment from Sanofi, increasing its total assets under management to over $1.4 billion.  Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in biotech and artificial intelligence/digital health companies that focus on helping patients, aiming to transform the… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #In vitro #In vivo

Navigating considerations for ADCs: Guidance for the industry

This paid-for advertorial from Eurofins appeared in DDW Volume 26 – Issue 4, Fall 2025   Antibody-drug conjugates (ADCs) are increasingly promising due to advances in biologics and chemistry. With 16 FDA-approved ADCs, clinical interest is growing, though development remains complex, requiring thorough evaluation of the antibody, linker, payload, and… Read More

#Exclusive Content

#Biopharmaceuticals #Drug discovery #High throughput screening #Sartorius

Advancing global health through innovation

This paid-for advertorial from Sartorius appeared in DDW Volume 26 – Issue 4, Fall 2025 The global health landscape is complex and constantly shifting, presenting multifaceted challenges for the pharmaceutical industry. To keep pace, companies must deliver more targeted therapies in less time, often with fewer resources. Advances in areas… Read More

#Exclusive Content

Long Covid
#Covid-19 #Japan #Therapeutic targets

Long Covid breakthrough offers hope of new therapeutic target

Researchers from Yokohama City University in Japan have made a breakthrough in understanding Covid ‘brain fog’, providing clues for a new therapeutic target.  Researchers used a novel imaging technique to visualise AMPA receptors (AMPARs), key molecules for memory and learning, in the living brain. They… Read More

#News

#AI #Innovation #UK

Lord Hague of Richmond opens new £1.2 billion UK innovation district

Lord Hague of Richmond, Chancellor of the University of Oxford, has opened a flagship £1.2 billion ($1.6 billion) global innovation district in Oxford in a boost to UK science, technology and AI sectors.  Oxford North, approximately one million square feet in size, is equipped with newly developed… Read More

#News

Marine Diatom colony
#Japan #Tropical disease

Research on marine sponges could help treat tropical disease

Marine sponges could hold the answer to treating leishmaniasis, a neglected tropical disease, according to new research by the Tokyo University of Science and the University of the Ryukyus in Japan.  A research team led by Associate Professor Kanami Mori-Yasumoto from the Faculty of Pharmaceutical Sciences at… Read More

#News

#Cancer research #Cancer Research UK #National Cancer Institute

Twelve research teams competing for cancer research grants

Twelve leading research teams from around the world have been shortlisted for Cancer Grand Challenges’ fifth funding round, competing to win up to £20 million ($27 million) each to tackle cancer’s most formidable challenges.  Launched in 2020 by Cancer Research UK and the US National Cancer Institute… Read More

#News

#Vaccines

Vaccine patent applications hit record high, new data reveals

Global vaccine patent applications hit a record high in the year to June 2025, according to data from intellectual property law firm Mathys & Squire.  The total number of applications increased to 1220 from 1135 the previous year, a 7% increase on the previous year and a… Read More

#News

#Antibodies #Gene therapy

Researchers develop new method for safer AAV gene therapies

Researchers at the HUN-REN Research Centre for Natural Sciences (HUN-REN TTK) have developed a new method for detecting neutralising antibodies (Nabs), offering the potential for safer and more successful AAV gene therapies.  The novel ‘Constant Serum Concentration’ (CSC) assay, published in the journal Nature Gene Therapy, correctly… Read More

#News

Myeloma cells
#Clinical trial #Myeloma

Phase I/IIa trial of myeloma treatment HDP-101 underway

The Phase I/IIa trial of HDP-101, an ATAC candidate for the treatment of relapsed or refractory multiple myeloma, is underway, biotech company Heidelberg Pharma has announced.  The Phase I/IIa trial will evaluate Cohort 9 of HDP-101 after the Safety Review Committee (SRC) confirmed that the 140 µg/kg dose… Read More

#News

Multiple myeloma
#Clinical trial #Myeloma

ACT appointed to conduct Phase IIa trial of POLB 001 

Specialist blood cancer trials organisation Accelerating Clinical Trials Limited (ACT) has signed an agreement with biopharmaceutical company Poolbeg Pharma to conduct the Phase IIa clinical trial of POLB 001.  The Phase IIa first-in-patient open-label, single-arm trial is titled TOPICAL (Trial of Prevention of ImmunoCytokine Adverse events in Myeloma). Read More

#News